Last reviewed · How we verify
AbobotulinumtoxinA (ABO)
AbobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
AbobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Moderate to severe glabellar lines (frown lines), Moderate to severe forehead lines, Moderate to severe crow's feet.
At a glance
| Generic name | AbobotulinumtoxinA (ABO) |
|---|---|
| Also known as | Dysport® |
| Sponsor | Hexsel Dermatology Clinic |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Neurology |
| Phase | FDA-approved |
Mechanism of action
AbobotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary muscle relaxation lasting 3-4 months. The effect is localized to injected muscles and is reversible as new nerve terminals form.
Approved indications
- Moderate to severe glabellar lines (frown lines)
- Moderate to severe lateral canthal lines (crow's feet)
- Moderate to severe forehead lines
Common side effects
- Headache
- Injection site pain
- Eyelid ptosis
- Brow ptosis
- Injection site edema
- Injection site erythema
Key clinical trials
- Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia (PHASE3)
- Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars (PHASE2, PHASE3)
- Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AbobotulinumtoxinA (ABO) CI brief — competitive landscape report
- AbobotulinumtoxinA (ABO) updates RSS · CI watch RSS
- Hexsel Dermatology Clinic portfolio CI